The Hindu·2 min read·medium

Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms

T
The Hindu Bureau
Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms
AI Summary

Aurobindo Pharma reported a 25.2% increase in net profit for the June quarter, driven by strong revenue growth in its U.S. and European formulation businesses. The company also announced the merger of three of its subsidiaries to streamline operations and reduce administrative overhead.

Generic drugmaker Aurobindo Pharma reported a 25.2% year-on-year (YoY) increase in consolidated net profit to ₹1,032 crore in the June quarter FY27.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesseconomyhealth

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in